Literature DB >> 15809357

Clomethiazole: mechanisms underlying lasting neuroprotection following hypoxia-ischemia.

Andrew N Clarkson1, Hanzhong Liu, Rosanna Rahman, David M Jackson, Ian Appleton, D Steven Kerr.   

Abstract

Damage after hypoxia-ischemia (HI) is observed in both cortical and subcortical regions. In this study, we employed a "Levine" rat model of HI (left carotid ligation + 1 h global hypoxia on PND-26) and used histological and electrophysiological paradigms to assess the long-term neuroprotective properties of clomethiazole (CMZ; a GABA(A) receptor modulator). Key enzymes involved in inflammation, namely nitric oxide synthase (NOS) and arginase, were also examined to assess potential CMZ mechanisms not involving GABA-R activation. Assessments were carried out 3 and 90 days post-HI. Extensive CNS lesions were evident after HI ipsilaterally at both short- and long-term intervals. CMZ significantly decreased the lesion size at 3 and 90 days (P<0.01; P<0.05). Evoked field potential analyses were used to assess hippocampal CA1 neuronal activity ex vivo. Electrophysiological measurements contralateral to the occlusion revealed impaired neuronal function after HI relative to short- and long-term controls (P<0.001, 3 and 14 days; P<0.01, 90 days), with CMZ treatment providing near complete protection (P<0.001 at 3 and 14 days; P<0.01 at 90 days). Both NOS and arginase activities were significantly increased at 3 days (P<0.01), with arginase remaining elevated at 90 days post-HI (P<0.05) ipsilaterally. CMZ suppressed the HI-induced increase in iNOS and arginase activities (P<0.001; P<0.05). These data provide evidence of long-term functional neuroprotection by CMZ in a model of HI. We further conclude that under conditions of HI, functional deficits are not restricted to the ipsilateral hemisphere and are due, at least in part, to changes in the activity of NOS and arginase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809357     DOI: 10.1096/fj.04-3367fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  14 in total

1.  Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy.

Authors:  Zhihui Qin; Jia Luo; Lawren VandeVrede; Ehsan Tavassoli; Mauro Fa'; Andrew F Teich; Ottavio Arancio; Gregory R J Thatcher
Journal:  J Med Chem       Date:  2012-07-24       Impact factor: 7.446

2.  Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on GABA(A) receptor potentiation.

Authors:  Lawren Vandevrede; Ehsan Tavassoli; Jia Luo; Zhihui Qin; Lan Yue; David R Pepperberg; Gregory R Thatcher
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 3.  The Arginase Pathway in Neonatal Brain Hypoxia-Ischemia.

Authors:  Jana Krystofova; Praneeti Pathipati; Jeffrey Russ; Ann Sheldon; Donna Ferriero
Journal:  Dev Neurosci       Date:  2019-04-17       Impact factor: 2.984

Review 4.  Endothelial mechanisms of endothelial dysfunction in patients with obstructive sleep apnea.

Authors:  Jing Feng; Dan Zhang; Baoyuan Chen
Journal:  Sleep Breath       Date:  2011-04-10       Impact factor: 2.816

5.  Inhibitory role for GABA in autoimmune inflammation.

Authors:  Roopa Bhat; Robert Axtell; Ananya Mitra; Melissa Miranda; Christopher Lock; Richard W Tsien; Lawrence Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-01       Impact factor: 11.205

6.  Pharmacological Preconditioning with GYKI 52466: A Prophylactic Approach to Neuroprotection.

Authors:  Chelsea S Goulton; Anna R Patten; John R Kerr; D Steven Kerr
Journal:  Front Neurosci       Date:  2010-08-03       Impact factor: 4.677

7.  The flavonoid, 2'-methoxy-6-methylflavone, affords neuroprotection following focal cerebral ischaemia.

Authors:  Andrew N Clarkson; Lily Boothman-Burrell; Zita Dósa; Raghavendra Y Nagaraja; Liang Jin; Kim Parker; Petra S van Nieuwenhuijzen; Silke Neumann; Emma K Gowing; Navnath Gavande; Philip K Ahring; Mai M Holm; Jane R Hanrahan; Joseph A Nicolazzo; Kimmo Jensen; Mary Chebib
Journal:  J Cereb Blood Flow Metab       Date:  2018-01-29       Impact factor: 6.200

8.  Perisynaptic GABA Receptors The Overzealous Protector.

Authors:  Andrew N Clarkson
Journal:  Adv Pharmacol Sci       Date:  2012-02-22

Review 9.  Mechanisms of endothelial dysfunction in obstructive sleep apnea.

Authors:  Amy Atkeson; Sanja Jelic
Journal:  Vasc Health Risk Manag       Date:  2008

10.  Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer.

Authors:  Yoshinori Ino; Rie Yamazaki-Itoh; Seiji Oguro; Kazuaki Shimada; Tomoo Kosuge; Jan Zavada; Yae Kanai; Nobuyoshi Hiraoka
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.